Drug Trial Radar · NCT05081245
ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)
Last checked: Nov 19, 2026Latest source record: May 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
168
Actual
Start
Sep 13, 2022
Primary completion
Mar 10, 2026
Study completion Apr 17, 2026
Sponsor
- Lead sponsor
- MapLight TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Oct 18, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
ML-004-002 is a multi-center, randomized, double-blind, parallel-group, placebo-controlled study that will enroll approximately 150 adolescent and adult subjects with ASD. The primary objective is to evaluate the efficacy of ML-004 compared with placebo in the improvement of social communication deficits in subjects with ASD.
Conditions
- Autism Spectrum Disorder
Interventions
ML-004 (IR)/(ER) tabletDrug
Participants will receive ML-004 once daily.
ML-004 PlaceboDrug
Participants will receive matching placebo once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in Autism Behavior Inventory (ABI)-Social Communication Domain ScoreTime frame: Baseline up to Day 110
Locations
29 sites in 3 countries. Site status is shown where the registry gives one.
Harmonex Neuroscience Research
Dothan, Alabama
Southwest Autism Research & Resource Center, Clinical Research
Phoenix, Arizona
Cortica Healthcare
Glendale, California
NRC Research Institute
Orange, California
Cortica
San Rafael, California
Yale Child Study Center
New Haven, Connecticut
Children's National Health System - The Children's Research Institute (CRI)
Washington D.C., District of Columbia
Abba Medical Group
Miami, Florida
APG Research, LLC
Orlando, Florida
University of South Florida Psychiatry and Behavioral Neurosciences
Tampa, Florida
Neurobehavioral Medicine Group
Bloomfield Hills, Michigan
University of Missouri, Thompson Center for Autism & Neurodevelopmental Disorders
Columbia, Missouri
Jersey Shore University Medical Center
Neptune City, New Jersey
Nathan Kline Institute for Psychiatric Research
Orangeburg, New York
Richmond Behavioral Associates
Staten Island, New York
Center for Autism and the Developing Brain, New York State Psychiatric Institute
White Plains, New York
Ohio State University Nisonger Center
Columbus, Ohio
Suburban Research Associates
Media, Pennsylvania
BioBehavioral Research of Austin
Austin, Texas
Red Oak Psychiatry Associates, PA
Houston, Texas
Road Runner Research, Ltd.
San Antonio, Texas
Family Psychiatry of The Woodlands
The Woodlands, Texas
Cedar Clinical Research
Draper, Utah
Virginia Commonwealth University
Richmond, Virginia
Brain and Mind Centre
Camperdown, New South Wales, Australia
The Royal Children's Hospital, Murdoch Children's Research Institute
Parkville, Victoria, Australia
OCT Research ULC (dba Okanagan Clinical Trials)
Kelowna, British Columbia, Canada
Lawson Health Research Institute/ London Health Sciences Centre
London, Ontario, Canada
Holland Bloorview Kids Rehabilitation Hospital
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.